生物爱奇艺治疗公司开始对rhu-pGSN进行第二期试验,以治疗中度至重度的ARDS,在75个地点招募600名患者. BioAegis Therapeutics initiates Phase 2 trial for rhu-pGSN to treat moderate-to-severe ARDS, enrolling 600 patients across 75 sites.
BioAegis Therapeutics 已启动重组人血浆凝溶胶蛋白 （rhu-pGSN） 的 2 期临床试验，旨在治疗中度至重度急性呼吸窘迫综合征 （ARDS），这是一种在美国每年影响许多患者的严重疾病。 BioAegis Therapeutics has initiated a Phase 2 clinical trial for recombinant human plasma gelsolin (rhu-pGSN) aimed at treating moderate-to-severe Acute Respiratory Distress Syndrome (ARDS), a serious condition affecting many patients annually in the U.S. 美国、加拿大、英国和欧盟75个地点的600名病人将参加这次试验,评估治疗的安全和效果。 The trial will enroll 600 patients across 75 sites in the U.S., Canada, the UK, and the EU, assessing the treatment's safety and efficacy. 这项研究得到了美国卫生与公众服务部的支持。 The study is supported by the U.S. Department of Health and Human Services.